Compare PRTA & CBAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PRTA | CBAN |
|---|---|---|
| Founded | 2012 | 1975 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 539.9M | 436.6M |
| IPO Year | 2013 | 1995 |
| Metric | PRTA | CBAN |
|---|---|---|
| Price | $10.88 | $19.69 |
| Analyst Decision | Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $19.00 | N/A |
| AVG Volume (30 Days) | ★ 403.1K | 332.4K |
| Earning Date | 05-07-2026 | 04-22-2026 |
| Dividend Yield | N/A | ★ 2.39% |
| EPS Growth | N/A | ★ 16.91 |
| EPS | N/A | ★ 1.59 |
| Revenue | ★ $814,000.00 | N/A |
| Revenue This Year | $1,111.38 | $35.41 |
| Revenue Next Year | N/A | $4.84 |
| P/E Ratio | ★ N/A | $12.65 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.32 | $14.63 |
| 52 Week High | $11.69 | $21.61 |
| Indicator | PRTA | CBAN |
|---|---|---|
| Relative Strength Index (RSI) | 58.19 | 40.21 |
| Support Level | $9.69 | $18.95 |
| Resistance Level | $10.90 | $21.21 |
| Average True Range (ATR) | 0.39 | 0.51 |
| MACD | 0.01 | -0.16 |
| Stochastic Oscillator | 50.36 | 16.38 |
Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.
Colony Bankcorp Inc is a bank holding company. The bank provides a broad range of banking services to its retail and commercial customers. Its product line includes loans to small and medium-sized businesses, residential and commercial construction and land development loans, commercial real estate loans, agri-business and production loans, residential mortgage loans, consumer loans, and a variety of demand, savings, and time deposit products. The company's segments include the Banking Division, Retail Mortgage Division and small business specialty lending divisions. It generates maximum revenue from the Banking Division.